Linda D. Bosserman

5.1k total citations · 2 hit papers
89 papers, 3.3k citations indexed

About

Linda D. Bosserman is a scholar working on Oncology, Economics and Econometrics and Cancer Research. According to data from OpenAlex, Linda D. Bosserman has authored 89 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 23 papers in Economics and Econometrics and 18 papers in Cancer Research. Recurrent topics in Linda D. Bosserman's work include Economic and Financial Impacts of Cancer (21 papers), Cancer Treatment and Pharmacology (17 papers) and Health Systems, Economic Evaluations, Quality of Life (14 papers). Linda D. Bosserman is often cited by papers focused on Economic and Financial Impacts of Cancer (21 papers), Cancer Treatment and Pharmacology (17 papers) and Health Systems, Economic Evaluations, Quality of Life (14 papers). Linda D. Bosserman collaborates with scholars based in United States, France and Canada. Linda D. Bosserman's co-authors include Gary H. Lyman, Armando E. Giuliano, Donald L. Weaver, Cheryl Perkins, Sarah Temin, Mark R. Somerfield, Stephen B. Edge, Edith A. Perez, Lisa A. Newman and Donald A. Podoloff and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Linda D. Bosserman

85 papers receiving 3.2k citations

Hit Papers

Sentinel Lymph Node Biops... 2014 2026 2018 2022 2014 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2014 762 citations Sarah Temin, Linda D. Bosserman et al. Journal of Clinical Oncology profile →
  2. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2017 375 citations Linda D. Bosserman et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Linda D. Bosserman 1.8k 1.1k 740 711 527 89 3.3k
Alain Lortholary 3.0k 1.7× 652 0.6× 544 0.7× 470 0.7× 530 1.0× 169 4.1k
Barry C. Lembersky 2.5k 1.3× 1.1k 1.0× 555 0.8× 663 0.9× 236 0.4× 82 3.3k
Roberto Petrioli 1.6k 0.9× 407 0.4× 330 0.4× 855 1.2× 246 0.5× 135 3.1k
Ben Tran 2.7k 1.5× 1.1k 0.9× 430 0.6× 679 1.0× 249 0.5× 61 4.0k
Guenther G. Steger 4.6k 2.5× 1.3k 1.2× 342 0.5× 617 0.9× 1.1k 2.0× 156 6.0k
R. Bryan Rumble 2.1k 1.2× 923 0.8× 561 0.8× 896 1.3× 511 1.0× 68 4.3k
Qin Zhou 1.7k 0.9× 704 0.6× 354 0.5× 1.7k 2.4× 223 0.4× 187 5.4k
Philippe Beuzeboc 3.9k 2.2× 2.4k 2.1× 1.1k 1.4× 1.6k 2.3× 1.4k 2.7× 243 7.6k
F. Cognetti 2.3k 1.3× 539 0.5× 258 0.3× 1.9k 2.7× 297 0.6× 129 4.8k
Jana Prausová 3.4k 1.9× 461 0.4× 577 0.8× 559 0.8× 297 0.6× 54 4.1k

Countries citing papers authored by Linda D. Bosserman

Since Specialization
Citations

This map shows the geographic impact of Linda D. Bosserman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda D. Bosserman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda D. Bosserman more than expected).

Fields of papers citing papers by Linda D. Bosserman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda D. Bosserman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda D. Bosserman. The network helps show where Linda D. Bosserman may publish in the future.

Co-authorship network of co-authors of Linda D. Bosserman

This figure shows the co-authorship network connecting the top 25 collaborators of Linda D. Bosserman. A scholar is included among the top collaborators of Linda D. Bosserman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda D. Bosserman. Linda D. Bosserman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jones, Veronica, Linda D. Bosserman, Sayeh Lavasani, et al.. (2024). UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan. Cancer Medicine. 13(16). e70096–e70096. 6 indexed citations
2.
Lee, Jin Sun, Susan E. Yost, Sierra Min Li, et al.. (2022). Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer. Cancers. 14(13). 3159–3159. 16 indexed citations
3.
Liu, Jennifer, Simran Padam, Daneng Li, et al.. (2020). Strategies to Improve Participation of Older Adults in Cancer Research. Journal of Clinical Medicine. 9(5). 1571–1571. 17 indexed citations
4.
Rugo, Hope S., Jack A. Di Palma, Debu Tripathy, et al.. (2019). The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Research and Treatment. 175(1). 5–15. 50 indexed citations
5.
Brooks, Gabriel A., Linda D. Bosserman, Isa Mambetsariev, & Ravi Salgia. (2017). Value-Based Medicine and Integration of Tumor Biology. American Society of Clinical Oncology Educational Book. 37(37). 833–840. 7 indexed citations
6.
Yardley, Denise A., Linda D. Bosserman, Joyce O’Shaughnessy, et al.. (2015). Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute. Breast Cancer Research and Treatment. 154(1). 89–97. 22 indexed citations
7.
8.
Vahdat, Linda T., Eduard Vrdoljak, Henry Gómez, et al.. (2013). Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. Journal of Geriatric Oncology. 4(4). 346–352. 7 indexed citations
9.
Yardley, Denise A., Lowell L. Hart, Linda D. Bosserman, et al.. (2012). Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen. Breast Cancer Research and Treatment. 137(2). 457–464. 33 indexed citations
10.
11.
Bosserman, Linda D., et al.. (2012). Correlation of drug‐induced apoptosis assay results with oncologist treatment decisions and patient response and survival. Cancer. 118(19). 4877–4883. 10 indexed citations
12.
Poznak, Catherine Van, Sarah Temin, Gary C. Yee, et al.. (2011). American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer. Journal of Clinical Oncology. 29(9). 1221–1227. 235 indexed citations
13.
Brufsky, Adam, W G Harker, J. Thaddeus Beck, et al.. (2011). Final 5‐year results of Z‐FAST trial. Cancer. 118(5). 1192–1201. 148 indexed citations
14.
Britten, Carolyn D., Richard S. Finn, Linda D. Bosserman, et al.. (2009). A Phase I/II Trial of Trastuzumab plus Erlotinib in Metastatic HER2-Positive Breast Cancer: A Dual ErbB Targeted Approach. Clinical Breast Cancer. 9(1). 16–22. 21 indexed citations
15.
16.
Gregory, Stephanie A., Delvyn C. Case, Linda D. Bosserman, et al.. (2003). Fourteen-Day CHOP Supported with Granulocyte Colony-Stimulating Factor in Patients with Aggressive Non-Hodgkin's Lymphoma: Results of a Phase II Study. Clinical Lymphoma. 4(2). 93–98. 10 indexed citations
17.
Gitlitz, Barbara J., et al.. (2003). A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer. 98(9). 1863–1869. 65 indexed citations
18.
Emmanouilides, Christos, Peter J. Rosen, Milhan Telatar, et al.. (2000). Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma. Clinical Lymphoma. 1(2). 146–151. 10 indexed citations
19.
Boling, E, et al.. (1993). Non-invasive measurements of bone mass in adult renal osteodystrophy. Bone. 14(3). 409–413. 23 indexed citations
20.
Licht, Jonathan D., Linda D. Bosserman, Janet W. Andersen, et al.. (1990). Treatment of low-grade and intermediate-grade lymphoma with intensive combination chemotherapy results in long-term, disease-free survival. Cancer. 66(4). 632–639. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alain Lortholary Breakdown of academic impact, for papers by Barry C. Lembersky Breakdown of academic impact, for papers by Roberto Petrioli Breakdown of academic impact, for papers by Ben Tran Breakdown of academic impact, for papers by Guenther G. Steger Breakdown of academic impact, for papers by R. Bryan Rumble Breakdown of academic impact, for papers by Qin Zhou Breakdown of academic impact, for papers by Philippe Beuzeboc Breakdown of academic impact, for papers by F. Cognetti Breakdown of academic impact, for papers by Jana Prausová
Rankless by CCL
2026